ArticleFrontiers in pharmacology2025
Exploring the mechanism of Qingre Yishen Xiaozheng formula in treating diabetic kidney disease via the HIF-1α/HO-1 signaling pathway: an integrated network pharmacology and experimental study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Neuroprotective effects of traditional Chinese medicine formulas in animal models of retinal degenerative diseases: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ethnopharmacological relevance: The Qingre Yishen Xiaozheng Formula (QRYSXZF) is a traditional Chinese medicine prescription developed based on the "clearing heat and resolving stasis" principle, clinically applied for the treatment of diabetic kidney disease (DKD). Aim of the study: To investigate the therapeutic effects of QRYSXZF on DKD and elucidate its underlying mechanisms through integrated network pharmacology and experimental validation, focusing on the HIF-1α/HO-1 signaling pathway and ferroptosis regulation. Materials and methods: Active components of QRYSXZF were screened using the TCMSP database (OB ≥ 30%, DL ≥ 0.18), and a herb-compound-target network was constructed via Cytoscape 3.8.0. DKD-related targets were retrieved from GeneCards, OMIM, and TTD databases. Protein-protein interaction (PPI) networks, GO/KEGG enrichment analyses, and molecular docking (PyMOL/AutoDock) were performed to predict core targets and pathways. Results: Network pharmacology identified 153 shared targets between QRYSXZF and DKD, with quercetin, kaempferol, and β-sitosterol as core active components, while KEGG analysis highlighted the HIF-1 signaling pathway as a key mechanism. In DKD rats, QRYSXZF significantly improved renal function by reducing BUN, Cys-C, KIM-1 and NGAL, attenuated oxidative stress through increasing SOD/GSH-Px and decreasing MDA, regulated iron metabolism by lowering SF and elevating TF, suppressed ferroptosis via upregulating GPX4/FTH1 and downregulating ACSL4/NCOA4, and inhibited HIF-1α/HO-1 pathway activation, with molecular docking confirming stable binding between QRYSXZF components and HIF1A/HMOX1. Conclusion: QRYSXZF alleviates DKD progression by modulating the HIF-1α/HO-1 pathway to reduce ferroptosis, oxidative stress, and iron overload, providing a scientific basis for its clinical application in DKD management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.